Stockholders Equity (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Dec. 31, 2020	Jul. 19, 2016	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019	Jan. 31, 2020
Stock-based compensation expense	$ 100,000		$ 15,000
Unrecognized stock-based compensation expense			$ 103,000
Number of shares granted			24,900		24,900
Exercise price							$ 11.17
Shares vested							8,300
Recognised stock based expenses			$ 900,000		$ 1,200,000
Common stock, shares authorized			20,000,000		20,000,000		20,000,000
2017 Plan [Member]
Unrecognized stock-based compensation expense					$ 1,800,000
Recognised stock based expenses			$ 835,000	$ (345,000)	$ 1,245,000	$ (596,000)
Granted shares description					This expense is expected to be recognized over of the next 2.25 years.
Common stock, shares authorized			360,000		360,000
Stock Repurchase Program [Member]
Inclusive of commissions					$ 1,671,188
Repurchase of outstanding common stock		2,500,000			152,801
Other Compensation Plans/Programs [Member]
Unrecognized stock-based compensation expense					$ 5,749
Common stick, granted awards					5,749
Common stock shares issued during period					152,801
Percentage of shares awarded			13300.00%		13300.00%
Expenses recognized period					The cost of these non-vested awards is expected to be recognized over a two-year weighted-average period.
2017 Plan
Stock-based compensation expense					$ 500,000
Restricted stock unit					21,000
Performance Based [Member]
Stock-based compensation expense					$ 700,000
Granted shares description					The total amount of previously recognized stock-based compensation attributable to the 2017 and 2018 grants that was reversed was approximately $0.8 million of which approximately $0.03 million related to the SARS.